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SUMMARY
The p53-regulated long non-coding RNA lincRNA-p21 has been proposed to act in trans via
several mechanisms ranging from repressing genes in the p53 transcriptional network to regulating
mRNA translation and protein stability. To further examine lincRNA-p21 function we generated a
conditional knockout mouse model. We find that lincRNA-p21 predominantly functions in cis to
activate expression of its neighboring gene, p21. Mechanistically, we show that lincRNA-p21 acts
in concert with hnRNP-K as a co-activator for p53-dependent p21 transcription. Additional
phenotypes of lincRNA-p21 deficiency could be attributed to diminished p21 levels, including
deregulated expression and altered chromatin state of some Polycomb target genes, defective G1/S
checkpoint, increased proliferation rates, and enhanced reprogramming efficiency. These findings
indicate that lincRNA-p21 affects global gene expression and influences the p53 tumor suppressor
pathway by acting in cis as a locus-restricted co-activator for p53-mediated p21 expression.
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INTRODUCTION
The p53 tumor suppressor pathway is activated in the presence of cellular stress, such as
DNA damage and oncogenic signaling, and in turn coordinates the transcriptional response
of hundreds of genes (Levine and Oren, 2009). Depending on the type of tissue and the
nature of the stress signal, p53 activation can initiate multiple pathways that can lead to a
temporary pause at a cell cycle checkpoint to allow for DNA repair, permanent growth arrest
(senescence), or cell death (apoptosis) (Vousden and Prives, 2009). It is not clear what
determines the outcome of p53 activation. Multiple phenomena, including the strength of
p53 binding at the promoters of target genes and the dynamics of p53 oscillations, have been
proposed to guide the transcriptional response leading to distinct cellular outcomes
(Vousden and Prives, 2009; Purvis et al., 2012).
Based on the identification of mouse long non-coding RNAs (lncRNAs) that are directly
induced by p53, recent studies have suggested that lncRNAs may provide an additional layer
of transcriptional regulation in the p53 pathway (Guttman et al., 2009; Huarte et al., 2010).
Among these, lincRNA-p21 has been proposed to promote apoptosis (Huarte et al., 2010).
Other p53-regulated lncRNAs, including Pint and PANDA, have been found to antagonize
p53 activity by promoting proliferation and by limiting the induction of pro-apoptotic genes
(Hung et al., 2011; Marin-Bejar et al., 2013). In addition, lncRNAs expressed from p53-
bound enhancer regions have been found to regulate checkpoint function (Melo et al.,
2013a). These studies support a model in which p53-regulated lncRNAs fine-tune the p53
transcriptional response.
In recent years, significant insight has been gained into the numerous mechanisms by which
lncRNAs function (Rinn and Chang, 2012). Some well-characterized nuclear lncRNAs, such
as XIST and lncRNAs expressed from imprinted loci, have been shown to modulate gene
expression in cis by acting as scaffolds for the recruitment of chromatin modifying
complexes, notably the PRC2 complex, and by altering the chromatin structure of target
genes (Lee and Bartolomei, 2013). Other cis-acting lncRNAs, such as enhancer RNAs
(eRNAs), have been suggested to activate gene expression by locally regulating chromatin
architecture (Melo et al., 2013b). In contrast, a growing class of lncRNAs, including
lincRNA-p21, has been proposed to regulate gene expression in trans by directing the
chromatin localization of protein binding partners (Fatica and Bozzoni, 2014). Finally, a
class of cytosolic lncRNAs, including human lincRNA-p21, has been proposed to regulate
mRNA translation and protein stability (Yang et al., 2014; Yoon et al., 2012).
Here, we have investigated the effects of lincRNA-p21 deficiency on the control of
expression of p53 target genes and on the p53-dependent cellular response in cells, derived
from a lincRNA-p21 conditional knockout mouse model. Our findings differ significantly
from previous studies, which used RNAi to deplete lincRNA-p21 levels, and highlight the
advantages of using a genetic system to study the function of low copy number, cis-acting
lncRNAs. The data presented here reveal a novel mechanism for regulation in the p53 tumor
suppressor network, whereby lincRNA-p21 acts as a transcriptional co-activator that locally
reinforces p21 activation past a functional threshold.
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RESULTS
Generation of lincRNA-p21 conditional knockout mice and cells
To investigate the role of lincRNA-p21 in vivo, we mutated the lincRNA-p21 locus using a
conditional gene targeting strategy. The targeting design was directed at preventing
expression of the lincRNA-p21 transcript by flanking the promoter region, which includes
the p53 response element (p53RE) as well as the first exon of lincRNA-p21, with loxP sites
(Fig. S1A, B). LincRNA-p21-deficient animals, generated by crossing founders to Deletor
Cre transgenic animals (Lewandoski et al., 1997), are viable, born at Mendelian ratios, and
display no significant abnormalities or predisposition to tumor development by the age of 18
months (Fig. S1A–E).
To characterize the function of lincRNA-p21, we isolated primary mouse embryonic
fibroblasts (MEFs) from littermate E13.5 embryos with lincRNA-p21−/− and +/+ genotypes,
as well as lincRNA-p21f/f; Rosa26-CreERT2 MEFs, in which lincRNA-p21 deletion could
be induced by treatment with tamoxifen. Loss of lincRNA-p21 expression was confirmed by
quantitative RT-PCR (qRT-PCR) and RNA-seq (Fig. S1F–H).
Deletion of lincRNA-p21 affects gene expression globally
To examine the role of lincRNA-p21 in the regulation of gene expression, we performed
global expression analysis. RNA was collected from three independent pairs of littermate
lincRNA-p21+/+ and lincRNA-p21−/− MEFs, harvested from untreated cells and at 24 hours
following treatment with the DNA damage-inducing agent doxorubicin. To identify
lincRNA-p21-responsive genes, we set a stringent classification in which high-confidence
differentially expressed genes (FDR<0.05) were required to show consistent variation of
34% or more (|Log 2 Fold Change|>0.43) in all three lincRNA-p21-deficient samples
compared to the corresponding littermate wild-type controls.
In the absence of DNA damage, we identified a set of 143 genes that were differentially
expressed between lincRNA-p21-proficient and –deficient samples (Fig. 1A left and Table
S1). To recognize statistically significant correlations with curated gene sets within the
Molecular Signature Database (MSigDB), we performed gene set enrichment analysis
(GSEA) and identified 122 gene sets affected by lincRNA-p21 loss (FDR<0.0001, Table S2)
(Subramanian et al., 2005). Connectivity maps revealed a pattern associated with increased
proliferation mediated by cell cycle regulators (Fig. 1C, top). We also noted that the cyclin-
dependent kinase inhibitor p21 (also known as CDKN1a/Cip1/WAF1), located 16.7 Kb
upstream of lincRNA-p21, was one of the differentially expressed genes. p21 is a direct
target of p53 transcriptional regulation that is induced upon passaging of primary cell
cultures as well as in response to cellular stress and acts to arrest cell cycle progression at
the G1/S checkpoint (Deng et al., 1995; Brugarolas et al., 1995). p21 expression levels were
reduced in all three lincRNA-p21-deficient MEF lines compared to wild-type controls (Fig.
S2C and Table S1). The novel roles of lincRNA-p21 in cell cycle control and in promoting
the expression of p21 will be examined in more detail below.
Using the identical approach, we next singled out 904 genes whose expression levels were
significantly altered in lincRNA-p21-deficient samples compared to wild-type controls
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following doxorubicin-induced DNA damage (Fig. 1A, right, B and Table S1). Enrichment
map summaries of the differentially expressed genes revealed correlations with gene sets
related to the doxorubicin response and the p53 pathway (Fig. 1C, bottom, FDR < 0.0001
and Table S2). Strikingly, GSEA also uncovered a negative correlation with multiple gene
sets associated with the Polycomb Repressive Complex 2, PRC2 (Fig. 1C). In fact, pathway
analysis using only the 649 genes that were downregulated in the doxorubicin-treated,
lincRNA-p21-deficient samples, indicated a strong overlap with PRC2 function. 7 out of the
top 12 MSigDB Chemical and Genetic Perturbations (CGP) categories represented gene sets
whose promoters were either occupied by components of the PRC2 complex (Eed and
Suz12) or carried the Polycomb chromatin signature (H3K27me3) in various cell types (Fig.
1D). The PRC2 complex, which plays an essential role in the epigenetic silencing of
regulatory genes controlling differentiation during embryonic development (Aldiri and
Vetter, 2012), has not previously been implicated in the DNA damage response or in the p53
pathway. However, multiple reports have shown important regulatory functions of lncRNAs
in the PRC2 pathway (Davidovich et al., 2013; Kaneko et al., 2013; Khalil et al., 2009; Zhao
et al., 2010).
Of note, comparison of the lincRNA-21-dependent genes identified here with the previously
published lincRNA-p21-regulated gene set (Huarte et al., 2010) showed no significant
overlap, despite the similarity in cell type (MEFs) and treatment (doxorubicin) (Fig. S2A–
C). This discrepancy is likely due to the different methods used to downregulate lincRNA-
p21 (potent genetic deletion versus RNAi-based post-transcriptional knockdown) and
highlights the importance of complementary genetic approaches to functional studies.
LincRNA-p21 promotes the expression of a set of DNA damage-inducible, PRC2-target
genes
Since PRC2 targets (defined by Benporath_PRC2_Targets gene set) were significantly
enriched in the lincRNA-p21-responsive gene set (Table S3), we investigated this
connection further, anticipating that these studies might shed light on the role of lncRNAs in
the regulation of Polycomb function. We observed that the majority of these genes were
lineage-specific transcription factors, whose expression is expected to be repressed by
Polycomb in primary MEFs and whose induction may be facilitating the activation of a
wider transcriptional response. Indeed, the expression of several genes selected from this set
was not detectable by qRT-PCR and by Western blotting in untreated samples (Fig. 2A).
However, these genes became strongly upregulated at 24 hours following doxorubicin
treatment and this induction was in part dependent on lincRNA-p21 (Fig. 2A and Fig. S3A,
B). Global expression analysis and qRT-PCR validation indicated that the effect of
lincRNA-p21 deficiency was limited to a subset of PRC2 target genes (Fig. S3B, C).
Importantly, since lincRNA-p21 is a p53-regulated gene, we confirmed that the expression
of this set of genes was also dependent on the p53 status (Fig. 2B), even though p53-binding
sites were not identified in the promoters of these genes (data not shown). Moreover,
induction of several of these genes could also be observed under other conditions that led to
p53-dependent lincRNA-p21 expression, such as in response to oncogenic stress following
restoration of p53 expression in a lung adenocarcinoma cell line (Fig. S3D) (Feldser et al.,
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2010). These data suggested an unanticipated connection between the p53-mediated stress
response, lincRNA-p21, and Polycomb-regulated genes.
LincRNA-p21 influences the chromatin state of Polycomb target genes
We next sought to determine the mechanism by which lincRNA-p21 regulated this subset of
PRC2 target genes. To test whether lincRNA-p21 regulated the chromatin state of its
responsive Polycomb target genes, we performed H3K27me3 and H3K4me3 ChIP-seq in
lincRNA-p21+/+ and −/− MEFs, harvested at 24 hours following mock or doxorubicin
treatment. Meta analysis of the loci of the lincRNA-p21-regulated, PRC2 target gene set
revealed that the PRC2-specific H3K27me3 modification was not affected by the
doxorubicin treatment or by lincRNA-p21 deficiency (Fig. 2C and Fig. S4A). In contrast,
whereas the activating H3K4me3 mark increased in wild-type cells in the presence of DNA
damage, it remained unchanged following doxorubicin treatment in lincRNA-p21−/− MEFs
(Fig. 2C, D, and Fig. S4A). Importantly, the effect of lincRNA-p21-deficiency did not lead
to global changes in chromatin state (Fig. 2E and Fig. S4B) and not all loci subject to
Polycomb regulation were affected (Fig. S4C). These data suggested that lincRNA-p21
status influenced the expression of a subset of DNA damage-inducible, PRC2 target genes
by affecting positive regulators associated with transcriptional activation, which, in these
cases, appeared to override the persistent H3K27me3 repressive mark.
LincRNA-p21 indirectly regulates PRC2 target genes via p21
We speculated that lincRNA-p21 may regulate the expression of the subset of PRC2 target
genes by exerting a global effect on chromatin regulation. However, by RNA
immunoprecipitation, we found no evidence for an interaction between lincRNA-p21 and
components of the repressive PRC2 complex or other chromatin modifiers (Huarte et al.,
2010 and data not shown). Moreover, the relatively low stability of lincRNA-p21 (half-life <
2 hours) and its low copy number (∼8 molecules/cell in the presence of DNA damage) were
not consistent with a functional role as a widespread trans-regulator (Fig. S5A, B).
We next considered the possibility that lincRNA-p21 may directly bind at the promoters of
PRC2 target genes and locally regulate the chromatin state at these sites. However, by single
molecule RNA fluorescent in situ hybridization (RNA FISH), we did not observe co-
localization between lincRNA-p21 RNA and a set of probes specific to the intron of the
lincRNA-p21-responsive, PRC2 target gene Ntn1, designed to indicate the transcription site
of this gene (Fig. S5C). These data suggested that lincRNA-p21 did not physically interact
with the loci of PRC2 target genes.
We therefore examined the possibility that lincRNA-p21 may affect the expression of PRC2
target genes indirectly. Since several reports have linked p21 and cellular differentiation
(Missero et al., 1996; Steinman et al., 1994; Zhang et al., 1999), we speculated that the
reduction of p21 levels observed by RNAseq in lincRNA-p21-deficient cells (Table S1)
might contribute to the deregulation of the PRC2 target genes. Indeed, by qRT-PCR we
found that all the examined lincRNA-p21-regulated, PRC2 target genes showed reduced
induction levels following doxorubicin treatment in p21-deficient MEFs compared to wild-
type controls (Fig. 3A). Moreover, by ChIP-qPCR we detected a reduction in the H3K4me3
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chromatin mark and no change in the H3K27me3 chromatin modification at the promoters
of Foxa2, Npas1, and Pou4f3, three genes randomly selected from the set of lincRNA-p21-
responsive, PRC2 targets (Fig. 3B). These data indicated that lincRNA-p21 and p21 played
similar roles in promoting the DNA damage-dependent induction of the identified set of
PRC2 target genes.
To establish whether lincRNA-p21 and p21 acted in the same pathway, we performed an
epistasis experiment. We downregulated p21 in lincRNA-p21+/+ and −/−MEFs using a
lentiviral short hairpin RNA (shRNA), which led to a greater than 90% knockdown of p21
(Fig. 3C). A luciferase-specific hairpin was used as a negative control. We found that both
lincRNA-p21-deficiency and p21 knockdown led to diminished DNA damage-dependent
induction of Foxa2, Npas1, and Pou4f3 (Fig. 3D). Importantly, combined loss of lincRNA-
p21 and p21 did not further exacerbate the effect (Fig. 3D). Based on these findings, we
concluded that the lincRNA-p21-dependent transcriptional induction of a subset of PRC2
target genes in response to genotoxic stress was mediated through its control of p21.
LincRNA-p21 activates the expression of p21
We therefore sought to dissect the role of lincRNA-p21 in the regulation of its neighboring
gene, p21 (Fig. 4A). By qRT-PCR, we confirmed that acute, tamoxifen-mediated depletion
of lincRNA-p21 from lincRNA-p21f/f; Rosa26-CreERT2 MEFs resulted in a reproducible
30–50% decrease of p21 RNA and protein levels over 2–3 cell divisions (Fig. 4B, C). The
effect appeared specific to p21 since loss of lincRNA-p21 did not affect the expression of
the gene distal to lincRNA-p21, Srsf3, and did not lead to a general defect in the activation
of the p53 pathway (Fig. 4B and data not shown).
We next asked whether the p53-dependent induction of p21 in response to DNA damage
was affected by lincRNA-p21 deficiency. We observed that in lincRNA-p21−/−MEFs treated
with γ-irradiation or doxorubicin, p21 was induced with the same kinetics as in wild-type
cells but the total p21 RNA and protein levels remained significantly reduced by 30–50%
compared to control cells (Fig. 4D–G and Fig. S6A). These data indicated that lincRNA-p21
positively regulates p21 levels in passaged primary MEFs and in response to genotoxic
stress.
The region of deletion in lincRNA-p21-deficient cells is located 16.7 Kb upstream of the
p21 transcription start site and contains binding sites for multiple transcription factors,
including p53 (Huarte et al., 2010), as well as chromatin features that are associated with
both promoter and enhancer regions. Therefore, it was formally possible that the observed
defect in p21 expression could be due to deletion of a previously unidentified enhancer
element located within the targeted region or due to loss of other non-coding transcripts
expressed from the lincRNA-p21 locus. To address concerns with the specificity of the
genetic model, we developed an independent approach to decrease lincRNA-p21 levels
using antisense oligonucleotides (ASOs), which can mediate efficient co-transcriptional
knockdown of nuclear RNAs in an RNase H-dependent manner (Vickers et al., 2003).
Transfection with two independent lincRNA-p21-specific ASOs, ASO1 and ASO3, led to
greater than 90% loss of lincRNA-p21 RNA levels at 24 hours following transfection,
whereas ASO2 failed produce an efficient knockdown (Fig. 4A, H and Fig. S6B). The levels
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of inhibition diminished over time as MEFs underwent cell division and diluted the ASOs
(Fig. 4H). Using this approach, we found that at 96 hours following transfection with ASO1
and ASO3, the levels of p21 were reproducibly reduced by 23±9% compared to cells treated
with a control, non-targeting ASO (Fig. 4I and Fig. S6B). As a control for off-target effects,
transfection of lincRNA-p21−/− MEFs with lincRNA-p21-specific ASOs did not further
decrease p21 levels (Fig. 4I). We also observed that in the context of irradiation-induced
DNA damage, transfection of wild-type MEFs with the two independent lincRNA-p21-
specific ASOs led to a decrease in p21 levels (23% and 45% with ASO1 and ASO3,
respectively) (Fig. 4J). Moreover, ASO-mediated lincRNA-p21 depletion in the context of
oncogenic stress (Feldser et al., 2010) similarly affected the expression of p21 by 50% (Fig.
S6C). Collectively, these experiments point to a specific role for the lincRNA-p21 transcript
in the positive regulation of p21 expression.
LincRNA-p21 regulates p21 in cis
Recent data suggest that lncRNAs can regulate nearby genes via either cis- or transacting
mechanisms (Fatica and Bozzoni, 2014). To visualize lincRNA-p21, we performed single
molecule RNA FISH and observed that in wild-type MEFs treated with doxorubicin,
lincRNA-p21 localized exclusively to the nucleus, with 63% of the cells containing 2 or 4
prominent lincRNA-p21 signals (Fig. 5A). As a negative control, over 90% of lincRNA-
p21−/− cells contained no detectable signals (Fig. 5A). To test whether lincRNA-p21 was
localized at or near its site of transcription, we designed RNA FISH probes complementary
to the intron of lincRNA-p21. Since introns are removed co-transcriptionally and quickly
degraded, we reasoned that the intron-specific RNA FISH signal should mark the genomic
locus from which lincRNA-p21 is expressed. In accordance with a cis model, we observed
perfect co-localization between lincRNA-p21 exonic and intronic signals in all wild-type
cells, in which we could detect the short-lived intronic signal (Fig. 5B).
To further distinguish between cis and trans mechanisms of action, we crossed lincRNA-
p21f/+ and p21−/− mice and isolated lincRNA-p21f/+; p21+/− MEFs, in which lincRNA-p21
and p21 mutations were in trans (Fig. 5C, top). In these cells, there was only one functional
allele of p21, which was physically linked to a floxed allele of lincRNA-p21. We observed
that upon adenoviral Cre-mediated deletion of the floxed allele of lincRNA-p21, the
expression of p21 from the same chromosome diminished by 41±2% (Fig. 5C, bottom),
which is comparable to the decrease of p21 levels in lincRNA-p21-deficient cells (Fig. 4B).
Thus, the wild-type allele of lincRNA-p21 located in trans could not rescue p21 levels. In
control experiments, we confirmed that the altered p21 expression required loss of lincRNA-
p21 (Fig. 5C).
Consistent with a model in which lincRNA-p21 acts on p21 exclusively in cis, exogenous
overexpression of lincRNA-p21 failed to rescue p21 levels in lincRNA-p21-deficient MEFs
(Fig. 5D). This is likely because the majority of the overexpressed RNA did not properly
localize to the endogenous locus and was exported to the cytoplasm (Fig. 5E).
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LincRNA-p21 recruits hnRNP-K to promote p53-dependent transcription of p21
We next addressed the mechanism by which lincRNA-p21 promoted p21 expression. It has
been established that p21 is a direct target of p53, but several transcriptional co-activators
have been implicated in the regulation of p21 expression (Jung et al., 2010). In particular,
studies in human cells have shown that one of these factors, hnRNP-K, binds to the p21
promoter in response to DNA damage and promotes p21 expression by recruiting p53 and/or
by stabilizing p53 binding (Moumen et al., 2005). Since previous work had uncovered a
direct interaction between lincRNA-p21 and hnRNP-K (Huarte et al., 2010), we speculated
that lincRNA-p21 may be involved in mediating the co-activator function of hnRNP-K at
the promoter of p21.
Consistent with previous data, we detected hnRNP-K and p53 at the p53RE in the p21
promoter by ChIP-qPCR in doxorubicin-treated, wild-type cells, despite the low efficiency
of hnRNP-K immunoprecipitation (less than 1%) (Fig. 6A–C and Fig. S7A). We next asked
whether lincRNA-p21 was required for the recruitment of hnRNP-K and p53 to the p21
promoter. ChIP-qPCR of hnRNP-K revealed that the binding of hnRNP-K at the p21 p53RE
was reduced to background levels in lincRNA-p21-deficient MEFs (Fig. 6B). Moreover, as
expected in the absence of proper localization of hnRNP-K at this site, we observed by
ChIP-qPCR that the strength of p53 binding at the p21 promoter was diminished by 43±12%
in lincRNA-p21-deficient cells compared to wild-type controls (Fig. 6C). Reduced binding
of p53 at the p21 promoter was also observed in MEFs in which lincRNA-p21 RNA levels
were downregulated by two independent lincRNA-p21-specific ASOs (ASO1 and ASO3)
compared to a control, non-targeting ASO, whereas ASO2, which does not lead to efficient
lincRNA-p21 downregulation (Fig. S6B), did not alter p53 binding (Fig. 6D). These data
suggested that lincRNA-p21 RNA is required for the recruitment of hnRNP-K to the p53RE
in the promoter of p21 and for the efficient binding of p53 at this site.
In line with a model whereby lincRNA-p21 and hnRNP-K cooperate to promote p21
transcription, knockdown of hnRNP-K led to diminished p21 levels in doxorubicin-treated
lincRNA-p21+/+ MEFs but not in lincRNA-p21−/− MEFs (Fig. 6E, F). Of note, hnRNP-K
downregulation also resulted in reduced lincRNA-p21 levels, suggesting that hnRNP-K is
required for the induction and/or stability of lincRNA-p21 (Fig. 6G)
LincRNA-p21 regulates the G1/S checkpoint, proliferation rates, and reprogramming
efficiency
Finally, we investigated the physiological consequence of lincRNA-p21 deficiency in
MEFs. Based on its role in regulating p21, which is a major mediator of checkpoint function
in the p53 pathway, we anticipated that lincRNA-p21 deletion might affect the G1/S
checkpoint. To test for this, we assayed the proportion of cells that entered S-phase
following γ-irradiation in lincRNA-p21-proficient and -deficient cells. Compared to control
cells, a significantly elevated fraction of lincRNA-p21−/− MEFs as well as MEFs transfected
with lincRNA-p21-specific ASOs, continued to incorporate BrdU in the presence of DNA
damage (Fig. 7A). This phenotype was comparable to the G1/S checkpoint defect observed
in p21-deficient MEFs (Fig. S7B). We concluded that the G1/S checkpoint was indeed
compromised in the absence of lincRNA-p21.
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Consistent with a defective checkpoint function, we reproducibly observed that lincRNA-
p21-deficient MEFs proliferated faster compared to wild-type controls, which is similar to
p21−/− cells (Fig. 7B and Fig. S7C). Moreover, we observed that lincRNA-p21-deficiency
significantly increased the reprogramming efficiency of primary MEFs, as indicated by
enhanced levels of the pluripotency marker Nanog and an increased number of alkaline
phosphatase-positive colonies in lincRNA-p21−/− compared to littermate, wild-type MEFs
(Fig. 7C, D).
In contrast, we did not find a role for lincRNA-p21 in other well-characterized functions of
the p53 pathway in MEFs, including apoptosis, the ability to promote senescence following
prolonged exposure to doxorubicin-induced DNA damage, and the capacity to inhibit
cellular transformation (Fig. S7D–F). These data are consistent with the absence of these
phenotypes in p21-deficient cells (Pantoja and Serrano, 1999). In sum, these data indicate
that loss of lincRNA-p21 leads to cellular phenotypes similar to the consequences of p21
deletion in MEFs.
DISCUSSION
An emerging class of lncRNAs, including lincRNA-p21, has been proposed to regulate the
expression of multiple genes in trans (Fatica and Bozzoni, 2014). For the most part, these
studies rely on global gene expression profiling, which identifies hundreds, sometimes
thousands, of differentially expressed genes in cells with RNAi-mediated knockdown or
genetic depletion of lncRNAs. From a mechanistic perspective, however, it is important to
differentiate direct targets of lncRNA regulation from genes that are indirectly affected by
lncRNA loss. For instance, we found by global expression analysis that genetic deletion of
lincRNA-p21 in primary MEFs led to the deregulation of close to one thousand genes.
However, we present several lines of evidence that do not support widespread trans-
regulatory activity of this lincRNA. First, single-molecule RNA FISH revealed that
lincRNA-p21 did not interact with multiple distinct loci but was localized primarily at or
near its transcription site. Next, we did not find evidence of nuclear domains near the
lincRNA-p21 locus that cluster lincRNA-p21-regulated genes (Engreitz et al., 2013).
Finally, the low copy number (∼8 lincRNA-p21 molecules/cell) does not support a global
function for lincRNA-p21 as a protein-binding partner. For these reasons, we believe it
unlikely that lincRNA-p21 has genome-wide regulatory functions.
The discrepancy with previous functional studies, which have proposed global nuclear and
cytosolic trans functions for lincRNA-p21 (Huarte et al., 2010; Yang et al., 2014; Yoon et
al., 2012), can likely be attributed to the different methods used to perform loss-of-function
analyses (genetic deletion vs RNAi) and to the different cell types (MEFs vs human cancer
cell lines). Importantly, a genetic deletion, rather than an RNAi approach, was required to
unveil the cis function of lincRNA-p21 in the regulation of p21. Additional advantages of
using a conditional knockout mouse model include specificity, efficiency, and opportunity to
study the long-term consequences of lincRNA-p21 depletion in vitro and in vivo.
Using our genetic approach, we present compelling evidence that lincRNA-p21 activates the
expression of its neighboring gene p21 by 30–50%. As several of the major phenotypes of
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lincRNA-p21-deficiency could be replicated by two independent lincRNA-p21-targeting
ASOs, we conclude that this enhancer-like phenotype is mediated by the lincRNA-p21 RNA
transcript and not through a genetic element located in the region of deletion. These data
also argue against a role for another RNA species expressed from the lincRNA-p21 locus in
these phenotypes and overcome concerns about non-specific consequences of altered
chromatin architecture in mutant cells. Of note, the lincRNA-p21 locus does not bear the
high H3K4me1/H3K4me3 ratio indicative of enhancer elements and lincRNA-p21 RNA has
a half-life in the range of hours, rather than minutes, both of which suggest that lincRNA-
p21 likely does not belong to the recently described class of eRNAs (Orom and Shiekhattar,
2011). However, we cannot exclude the possibility that lincRNA-p21 may arise from an
enhancer region (Melo et al., 2013b).
Importantly, we formally show that lincRNA-p21 regulates p21 in cis. This conclusion is
substantiated by a genetic experiment in which we place lincRNA-p21 and p21 mutations in
trans as well as by the predominant two-dot nuclear pattern of lincRNA-p21 by RNA FISH
and by the inability to rescue phenotypes of lincRNA-p21 deficiency by exogenous
expression of lincRNA-p21. Consistent with our finding of cis regulation, the majority of the
cellular phenotypes and expression changes observed in lincRNA-p21-deficient cells could
be attributed to the role of lincRNA-p21 in activating p21, including defects in the G1/S cell
cycle checkpoint and in proliferation control. Conversely, p21-independent functions of the
p53 pathway in MEFs, including the abilities to promote apoptosis and senescence and the
capacity to inhibit oncogene-mediated cellular transformation, were not affected by loss of
lincRNA-p21. The lack of an overt organismal phenotype in lincRNA-p21-deficient mice is
also in agreement with a cis regulatory model, given that p21-deficient animals develop
normally and exhibit only mild susceptibility to tumor development with a long average
latency (Martin-Caballero et al., 2001).
In further support of a cis regulatory model, we provide direct evidence that the regulation
of a subset of PRC2 target genes by lincRNA-p21 is mediated through p21. This observation
reveals a novel function of the p53 pathway. It remains to be determined what the
physiological purpose of de-repression of PRC2 targets in response to prolonged genotoxic
stress may be. One potential function could be the elimination of damaged cells by
promoting terminal differentiation through the expression of multiple lineage-specific
factors. This model is consistent with a growing body of literature that has linked p21
function in growth arrest with cellular differentiation and organism development (Munoz-
Espin et al., 2013). Moreover, this phenomenon might be related to the increased
reprogramming rates observed in p53-, p21-, and lincRNA-p21-deficient primary MEFs
(Hanna et al., 2009; Kawamura et al., 2009). Whereas this phenotype was originally
attributed to increased cellular proliferation rates, cell intrinsic factors were also
acknowledged as potential modulators of the transition to a pluripotency state (Hanna et al.,
2009).
The data presented here indicate that lincRNA-p21 acts in concert with hnRNP-K to
promote p53-mediated expression of p21. Our findings support a model in which lincRNA-
p21 and hnRNP-K act as transcriptional co-activators for local p53-mediated transcription.
We propose that hnRNP-K binds directly to lincRNA-p21, which serves to promote the
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stability of lincRNA-p21 as well as to target hnRNP-K to the p21 locus. In the presence of
lincRNA-p21 and hnRNP-K, p53 can carry out efficient induction of p21. These findings are
consistent with previous studies in human cells that have implicated hnRNP-K as a
transcriptional co-activator for p53-mediated expression of p21 (Moumen et al., 2005). An
intriguing question is how lincRNA-p21 deficiency, which affects p21 expression levels by
only 30–50%, leads to the range and extent of phenotypes that are comparable to complete
loss of p21. We propose that lincRNA-p21-mediated reinforcement of activation may push
p21 past a threshold for response and thus facilitate finer regulation of cellular responses.
It is important to understand the role of reinforcing p21 expression in cis. We speculate that
this may be key in the context of the p53 tumor suppressor pathway, which is complex and
whose outcome can be cell type- and context-specific (Vousden and Prives, 2009). p21 and
hundreds of other genes are activated by p53 in response to stress and different targets have
been shown to dictate different cellular outcomes (Levine and Oren, 2009). Thus, a function
of lincRNA-p21 and hnRNP-K may be to locally amplify the execution of a specific p53-
dependent transcription output, reliant on sustained p21 activation. The contribution of
lincRNA-p21 is to recruit hnRNP-K in a locus-restricted manner and maintain p21
activation.
In summary, these data point to lincRNA-p21 as a key modulator of gene expression in the
p53 pathway, influencing the activation and the chromatin state of hundreds of genes
through its cis control of p21 expression. This work highlights the power of using defined
genetic systems to dissect the contribution of lncRNAs to complex biological pathways. The
model presented here has general implications for how low copy number, cis-acting
lncRNAs may locally reinforce the specificity of broad transcriptional programs.
EXPERIMENTAL PROCEDURES
Mouse strains, cell culture, and treatments
LincRNA-p21 floxed and null mice and E13.5 MEFs were generated as described in
Extended Experimental Procedures. Rosa26-CreERT2 (Ventura et al., 2007) and p21 mice
(The Jackson Laboratory, stock number 003263) have previously been described .
To delete lincRNA-p21 in lincRNA-p21f/f; Rosa26-CreERT2 MEFs, cells were treated with
0.5 µM 4-OHT. To delete lincRNA-p21 in lincRNA-p21f/+; p21+/− MEFs, cells were
infected 2 times at a 24-hour interval with Cre recombinase or control GFP adenovirus. To
induce DNA damage, cells were treated with 0.5 µM doxorubicin or irradiated with 2 or 10
Gy of γ-irradiation and harvested at indicated time-points following treatment.
5–10-5 MOE gapmer oligonucleotides were designed and generously provided by Isis
Pharmaceuticals (Table S4). 1 µM lincRNA-p21-specific or non-targeting control ASOs
were transfected twice at a 48-hour interval into 1×106 lincRNA-p21+/+ and −/− MEFs using
the Amaxa Mouse/Rat Hepatocyte Nucleofector Kit (Lonza) and the Nucleofector 2b Device
(Lonza).
Dimitrova et al. Page 11
Mol Cell. Author manuscript; available in PMC 2015 June 05.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Constructs
Full-length mouse lincRNA-p21 cDNA (a gift from John Rinn) was expressed from the
pSLIK lentiviral expression system (Shin et al., 2006). pLKO p21 and hnRNP-K hairpins
were purchased from The RNA Consortium (TRC) collection (Thermo Scientific) (p21:
clone IDs TRCN0000042583 (sh#1) and TRCN0000042584 (sh#2, used to replicate data);
hnRNP-K: TRCN0000096825 (sh#4)). Lentivirus was produced as described in Extended
Experimental Procedures.
RNA isolation and RT-qPCR
RNA was isolated with RNeasy Mini Kit (Qiagen) and reverse transcribed using High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems). SYBR Green PCR master
mix (Applied Biosystems) was used for qPCR with primers listed in Table S4. Expression
levels were calculated relative to GAPDH and normalized to control samples.
Western blotting
Western blotting was performed with whole cell lysates, using the following antibodies: p21
(clone F-5, sc-6246, Santa Cruz Biotechnology), hnRNP-K (ab70492, Abcam), H3K4me3
(ab8580, Abcam), H3K27me3 (ab6002, Abcam), and loading control β-tubulin (ab6046,
Abcam).
Chromatin immunoprecipitation (ChIP)
ChIP was performed as described in Extended Experimental Procedures with the following
antibodies: H3K4me3 (ab8580, Abcam), H3K27me3 (ab6002, Abcam), p53 (clone CM5,
VP-P956, Vector Laboratories), hnRNP-K (ab70492, Abcam), and control IgG (ChIP grade,
ab46540, Abcam). DNA was submitted for high-throughput sequencing (ChIP-seq) or used
for qPCR analysis (ChIP-qPCR) using primers listed in Table S4. The data represent the
percentage of input that was immunoprecipitated.
Single molecule RNA- Fluorescence in situ hybridization (RNA-FISH)
Single molecule RNA FISH was performed as previously described (Raj et al., 2008) with
probes listed in Table S4.
G1/S checkpoint assay
G1/S checkpoint assay was performed as previously described (Brugarolas et al., 1995) with
modifications (see Extended Experimental Procedures). The data represent the fraction of
BrdU-positive cells in irradiated samples relative to non-irradiated samples for each cell
line.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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HIGHLIGHTS
• Murine knockout model reveals a role for lincRNA-p21 in activating p21 in cis
• LincRNA-p21 acts with hnRNP-K as a transcriptional co-activator of p53
• LincRNA-p21 promotes the expression of a set of Polycomb target genes via
p21
• LincRNA-p21 regulates the G1/S checkpoint, proliferation, and reprogramming
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Figure 1. Loss of lincRNA-p21 affects gene expression globally
(A) Heatmaps of differentially expressed genes (Table S1) in untreated (left) and
doxorubicin (Doxo)-treated (right) pairs of littermate lincRNA-p21-proficient (WT) and –
deficient (KO) MEFs, FDR<0.05, |Log2 Fold change KO/WT| >0.43 in all three biological
replicates.
(B) Venn diagram of the overlap of the lincRNA-p21-reponsive genes in the presence and
absence of doxorubicin (Doxo).
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(C) Connectivity maps of gene sets based on GSEA of differentially expressed genes in (A)
(Table S2, FDR<0.0001). Red nodes represent enrichment with loss of lincRNA-p21 and
blue represents enrichment in wild-type cells. Node size reflects the number of genes in each
set and edge thickness reflects the overlap between the sets.
(D) Top 12 categories of GSEA of 649 lincRNA-p21-responsive, doxorubicin-regulated
genes using the CGP Collection of MSigDB. Gene sets related to the PRC2 pathway are
highlighted in blue. k indicates the number of lincRNA-p21-responsive genes; K represents
the number of genes included in a given gene set. See also Figures S1 and S2 and Tables 1
and 2.
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Figure 2. LincRNA-p21 promotes the expression and influences the chromatin state of a set of
DNA damage-inducible, PRC2-target genes
(A–B) qRT-PCR analysis of selected lincRNA-p21-responsive, PRC2 target genes in
indicated MEFs and treatments. Data, replicated in >3 independent experiments, are
represented mean±SEM of technical replicates. (Inset) Immunoblot analysis of Foxa2.
(C) Meta plots of the genic H3K27me3 (left) and promoter-associated H3K4me3 (right)
ChIP-seq enrichment levels at lincRNA-p21-responsive, PRC2 target genes in indicated
MEFs and treatments.
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(D) Genome browser snapshot of Foxa2 locus, related to ChIP-seq in (C).
(E) Immunoblot analysis of H3K4me3 and H3K27me3 protein levels in whole cell extracts
of doxorubicin-treated MEFs. Total H3 was used as a loading control. See also Figures S3,
S4 and Table S4.
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Figure 3. LincRNA-p21 regulates PRC2 target genes through p21
(A) Bar plot of normalized RNA levels of selected lincRNA-p21-regulated, PRC2 target
genes in indicated cells, analyzed by qRT-PCR. Data are represented as mean±SEM, n=3.
(B) ChIP-qPCR analysis of the enrichment of H3K4me3 (left) and H3K27me3 (right) at the
promoters of the indicated genes in doxorubicin-treated MEFs. Data, replicated in 2
independent experiments, are represented as mean±SEM of technical replicates.
(C) qRT-PCR analysis of lincRNA-p21 (left) and p21 (right) in a lincRNA-p21f/f; CreERT2
MEF line, infected with p21- or control luciferase (L)-specific shRNAs, harvested at 96
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hours following mock treatment or tamoxifen (Tam)-mediated deletion of lincRNA-p21 and
at 24 hours following mock treatment or doxorubicin (Doxo)-induced DNA damage. Data
are represented as mean±SEM of technical replicates.
(D) qRT-PCR analysis of the effects of the treatments described in (C) on the expression
levels of indicated lincRNA-p21-regulated, PRC2 target genes. Data were confirmed with an
independent p21-targeting shRNA (not shown). See also Figure S5 and Table S4.
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Figure 4. LincRNA-p21 RNA activates p21
(A) Schematic of the lincRNA-p21/p21 locus, the targeting strategy, the positions of
p53REs (*) in the promoters of lincRNA-p21 and p21, and the target sequences of lincRNA-
p21-specific ASO1 and ASO3.
(B) qRT-PCR analysis of lincRNA-p21, p21, and Srsf3 RNA levels in indicated MEFs at
indicated time-points after tamoxifen (Tam) treatment. Data, replicated in 2 independent
experiments, are represented as mean±SEM of technical replicates.
(C) Immunoblot analysis of p21 protein levels in MEFs described in (B). β-tubulin was used
as a loading control.
(D–E) qRT-PCR and immunoblot analysis of p21 in MEFs of indicated genotypes,
harvested 8 hours following treatment with the indicated doses of γ-irradiation (IR). Data,
replicated in 2 independent experiments, are represented as mean±SEM of technical
replicates.
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(F–G) qRT-PCR and immunoblot analysis of p21 in MEFs of indicated genotypes,
harvested untreated or 8 hours following doxorubicin (Doxo) treatment. Data are
represented as mean±SEM, n=8, p<0.0001, paired t-test.
(H) qRT-PCR analysis of lincRNA-p21 RNA levels at indicated time-points following
transfection with the indicated control non-targeting or lincRNA-p21-specific ASOs. (I)
qRT-PCR analysis of p21 RNA levels at 96 h following two consecutive ASO transfections,
performed at a 48 h interval, in MEFs of indicated genotypes. Data are represented as mean
±SEM, n=4, p=0.0318, paired t-test.
(J) qRT-PCR analysis of p21 RNA levels in ASO-treated wild-type MEFs, harvested 20 h
post 5 Gy irradiation. Data are represented as mean±SEM of technical replicates. See also
Figure S6 and Table S4.
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Figure 5. LincRNA-p21 regulates p21in cis
(A) Single molecule RNA FISH detection of lincRNA-p21 with exon-specific probes in
indicated MEFs (white arrows). DNA was counterstained with DAPI. % represents the
fraction of cells with indicated number of signals per cell (n=150).
(B) Co-localization of exon- and intron-specific lincRNA-p21 signals using single molecule
RNA FISH.
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(C) (Top) Schematic. (Bottom) qRT-PCR analysis of lincRNA-p21 and p21 RNA levels in
MEFs of indicated genotypes and treatments. Data are represented as mean±SEM, n=3,
p<0.0001, paired t-test.
(D) qRT-PCR analysis of lincRNA-p21 (top) and p21 (bottom) RNA levels in MEFs of
indicated genotypes, expressing TRE-lincRNA-p21, in the presence or absence of
doxorubicin (Doxo) and doxycycline (Doxy). Data, replicated in 2 independent experiments,
are represented as mean±SEM of technical replicates.
(E) Single molecule RNA-FISH detection of exogenously expressed lincRNA-p21 in
(D).See also Table S4.
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Figure 6. LincRNA-p21 acts with hnRNP-K as a transcriptional co-activator of p53-mediated
expression of p21
(A) Schematic of the positions of qPCR primers used for ChIP analysis, indicating the
distance (base pairs) relative to the p21 transcription start site (TSS).
(B) A representative hnRNP-K ChIP-qPCR analysis in indicated MEF lines, harvested 8
hours following doxorubicin treatment. Data, replicated in 4 independent experiments, are
represented as mean±SEM of technical replicates (n=4, p=0.0020, paired t-test).
(C) A representative p53 ChIP-qPCR analysis using the −2990 (p53RE) primer set in
indicated MEF lines, harvested 8 hours following doxorubicin treatment. Data, replicated in
3 independent experiments, are represented as mean±SEM of technical replicates (n=3,
p=0.043, paired t-test).
(D) ChIP-qPCR analysis of the relative p53 binding at the −2990 (p53RE) site of the p21
promoter in ASO-treated wild type MEFs. Data are represented as mean±SEM of technical
replicates.
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(E–G) qRT-PCR analysis of (E) hnRNP-K, (F) p21 (mean±SEM , n=4, p=0.0326, paired t-
test), and (G) lincRNA-p21 (mean±SEM , n=3, p=0.0030, paired t-test) levels in indicated
MEFs, expressing luciferase (luci) or hnRNP-K (K)-specific shRNAs, harvested at 8 hours
following doxorubicin treatment. See also Figure S7A and Table S4.
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Figure 7. LincRNA-p21 controls the G1/S checkpoint, proliferation, and the induction of
pluripotency
(A) (Top) Schematic of the G1/S checkpoint assay. (Bottom, left) FACS analysis of the
fraction of BrdU-positive cells in irradiated samples relative to untreated cells. Data are
represented as mean±SEM, n=4, p=0.0060, paired t-test. (Bottom, right) FACS analysis of
the fraction of BrdU-positive cells in wild type samples, transfected with the indicated
ASOs.
(B) Proliferation of lincRNA-p21+/+ and −/− MEFs isolated from littermates.
(C) qRT-PCR analysis of lincRNA-p21, p21, and Nanog levels in RNA harvested from
lincRNA-p21-proficient and –deficient cells at 6 days following infection with the
reprogramming factors Oct4, Sox2, Klf4, and Myc (OSKM). Data are represented as mean
±SEM, n=3, p=0.0004, paired t-test.
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(D) Images of alkaline phosphatase-positive colonies stained 6 days following infection of
MEFs with indicated genotypes with OSKM.
See also Figure S7B–F and Table S4.
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